PMID- 22561401
OWN - NLM
STAT- MEDLINE
DCOM- 20121109
LR  - 20131121
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 126
IP  - 2
DP  - 2012 Aug
TI  - Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy 
      in Finland.
PG  - 241-4
LID - 10.1016/j.ygyno.2012.04.045 [doi]
AB  - OBJECTIVE: Primary fallopian tube carcinoma (PFTC) is a rare malignancy and only 
      sparse data exist on its possible association with postmenopausal hormone therapy 
      (HT). We therefore studied this association in a nationwide cohort of Finnish HT 
      users. METHODS: All women> 50 years using systemic estradiol-only therapy (ET) 
      (n=117,820 hysterectomized women) or estradiol-progestin therapy (EPT) (n=247,781 
      nonhysterectomized women) for >/= 6 months during 1994-2008 were identified from 
      the national medical reimbursement register. The incidence of PFTC in HT users 
      was compared to that in the comparable background population (standardized 
      incidence ratio, SIR, with 95% confidence interval, CI). RESULTS: A total of 160 
      cases of PFTC were encountered in users of ET (n=34) or EPT (n=126). The use of 
      EPT >/= 5 years was accompanied by an increased risk for PFTC (SIR 2.15; 95% CI 
      1.66-2.72). The SIR increased further to 3.36 (95% CI 2.02-5.24) when EPT use 
      lasted >/= 10 years. The EPT-related risk for PFTC was restricted to the sequential 
      EPT and it was not seen for continuous EPT. Two leading progestins in EPT, 
      norethisterone acetate and medroxyprogesterone acetate, associated with 
      comparable risk elevations. ET use was not associated with the risk for PFTC. 
      CONCLUSIONS: The long-term, sequential use of EPT associates with an increased 
      risk for PFTC. In absolute terms, 4 additional cases of PFTC would be detected in 
      10-year follow-up of 10,000 women who have used EPT for at least 5 years.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Koskela-Niska, Virpi
AU  - Koskela-Niska V
AD  - Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, 
      PO Box 140, FI-00029 HUS, Finland. virpi.koskela-niska@fimnet.fi
FAU - Riska, Annika
AU  - Riska A
FAU - Lyytinen, Heli
AU  - Lyytinen H
FAU - Pukkala, Eero
AU  - Pukkala E
FAU - Ylikorkala, Olavi
AU  - Ylikorkala O
LA  - eng
PT  - Journal Article
DEP - 20120502
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Progestins)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Cohort Studies
MH  - Estradiol/administration & dosage
MH  - Estrogen Replacement Therapy/adverse effects/*statistics & numerical data
MH  - Fallopian Tube Neoplasms/chemically induced/*epidemiology
MH  - Female
MH  - Finland/epidemiology
MH  - Humans
MH  - Hysterectomy
MH  - Middle Aged
MH  - Progestins/administration & dosage
EDAT- 2012/05/09 06:00
MHDA- 2012/11/10 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/03/10 00:00 [received]
PHST- 2012/04/24 00:00 [revised]
PHST- 2012/04/26 00:00 [accepted]
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/11/10 06:00 [medline]
AID - S0090-8258(12)00333-2 [pii]
AID - 10.1016/j.ygyno.2012.04.045 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2012 Aug;126(2):241-4. doi: 10.1016/j.ygyno.2012.04.045. Epub 2012 
      May 2.